JP2004513076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513076A5 JP2004513076A5 JP2002514095A JP2002514095A JP2004513076A5 JP 2004513076 A5 JP2004513076 A5 JP 2004513076A5 JP 2002514095 A JP2002514095 A JP 2002514095A JP 2002514095 A JP2002514095 A JP 2002514095A JP 2004513076 A5 JP2004513076 A5 JP 2004513076A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- indol
- phenoxy
- pharmaceutical composition
- trifluoromethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 29
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 239000003112 inhibitor Substances 0.000 description 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 6
- 208000032928 Dyslipidaemia Diseases 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 208000006575 hypertriglyceridemia Diseases 0.000 description 5
- 230000004968 inflammatory condition Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 4
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 4
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 4
- 102000023984 PPAR alpha Human genes 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- -1 cyclopropylidene Chemical group 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229960002797 pitavastatin Drugs 0.000 description 3
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 3
- 229960002965 pravastatin Drugs 0.000 description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- HIPJZUFYVANNKA-UHFFFAOYSA-N 2-[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(CC=2C(=CC=CC=2)OC(C)(C)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 HIPJZUFYVANNKA-UHFFFAOYSA-N 0.000 description 2
- NJQKVYQTUIWJEQ-UHFFFAOYSA-N 2-[3-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(CC=2C=C(OC(C)(C)C(O)=O)C=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 NJQKVYQTUIWJEQ-UHFFFAOYSA-N 0.000 description 2
- GWYAJCNLNHXXBS-UHFFFAOYSA-N 2-[4-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 GWYAJCNLNHXXBS-UHFFFAOYSA-N 0.000 description 2
- QEAQRCMOQDLSRU-UHFFFAOYSA-N 2-[4-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]propanoic acid Chemical compound CC1=C(CC=2C=CC(OC(C)C(O)=O)=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 QEAQRCMOQDLSRU-UHFFFAOYSA-N 0.000 description 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 2
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940123064 Glycosyl transferase inhibitor Drugs 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 108010015181 PPAR delta Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940064856 azulfidine Drugs 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 2
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001906 cholesterol absorption Effects 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950002375 englitazone Drugs 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical class C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003297 glycosyltransferase inhibitor Substances 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960004738 nicotinyl alcohol Drugs 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- BWTOBMCYVACNJZ-QGZVFWFLSA-N (2r)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)O[C@H](C)C(O)=O)=C1C BWTOBMCYVACNJZ-QGZVFWFLSA-N 0.000 description 1
- XEWADPLLFDGPAT-GOSISDBHSA-N (2r)-2-[3-[2-[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]ethyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CCC=2C=C(O[C@H](C)C(O)=O)C=CC=2)=C1C XEWADPLLFDGPAT-GOSISDBHSA-N 0.000 description 1
- OFCWBJAYEIROGZ-QGZVFWFLSA-N (2r)-2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(O[C@H](C)C(O)=O)C=CC=2)=C1C OFCWBJAYEIROGZ-QGZVFWFLSA-N 0.000 description 1
- APRSDJAYLLJNFZ-LJQANCHMSA-N (2r)-2-[3-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@@H](C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C=C4C=CC=CC4=CC=3)C=2C)=C1 APRSDJAYLLJNFZ-LJQANCHMSA-N 0.000 description 1
- BWTOBMCYVACNJZ-KRWDZBQOSA-N (2s)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)O[C@@H](C)C(O)=O)=C1C BWTOBMCYVACNJZ-KRWDZBQOSA-N 0.000 description 1
- VIPDVHYKCSTTSQ-INIZCTEOSA-N (2s)-2-[3-[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(C=2C=C(O[C@@H](C)C(O)=O)C=CC=2)=C1C VIPDVHYKCSTTSQ-INIZCTEOSA-N 0.000 description 1
- OFCWBJAYEIROGZ-KRWDZBQOSA-N (2s)-2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(O[C@@H](C)C(O)=O)C=CC=2)=C1C OFCWBJAYEIROGZ-KRWDZBQOSA-N 0.000 description 1
- APRSDJAYLLJNFZ-IBGZPJMESA-N (2s)-2-[3-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C=C4C=CC=CC4=CC=3)C=2C)=C1 APRSDJAYLLJNFZ-IBGZPJMESA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- ADWNMHCJSZMYGA-UHFFFAOYSA-N 2-[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]acetic acid Chemical compound CC1=C(CC=2C(=CC=CC=2)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 ADWNMHCJSZMYGA-UHFFFAOYSA-N 0.000 description 1
- XICCHOADKSBRIM-UHFFFAOYSA-N 2-[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]propanoic acid Chemical compound CC1=C(CC=2C(=CC=CC=2)OC(C)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 XICCHOADKSBRIM-UHFFFAOYSA-N 0.000 description 1
- SGUDWIZALUVLKT-UHFFFAOYSA-N 2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)OC(C)(C)C(O)=O)=C1C SGUDWIZALUVLKT-UHFFFAOYSA-N 0.000 description 1
- FGVYFLHVBPQNQC-UHFFFAOYSA-N 2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)OCC(O)=O)=C1C FGVYFLHVBPQNQC-UHFFFAOYSA-N 0.000 description 1
- BWTOBMCYVACNJZ-UHFFFAOYSA-N 2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)OC(C)C(O)=O)=C1C BWTOBMCYVACNJZ-UHFFFAOYSA-N 0.000 description 1
- CPJTXKYXYBHVIM-UHFFFAOYSA-N 2-[2-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC=C1CC(C1=CC(OC(F)(F)F)=CC=C11)=C(C)N1C(=O)C1=CC=C(C=CC=C2)C2=C1 CPJTXKYXYBHVIM-UHFFFAOYSA-N 0.000 description 1
- JBRSATVQAGDEBO-UHFFFAOYSA-N 2-[3-[[1-(2,4-dichlorobenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C(=CC(Cl)=CC=3)Cl)C=2C)=C1 JBRSATVQAGDEBO-UHFFFAOYSA-N 0.000 description 1
- YGIKSALMJUFCTG-UHFFFAOYSA-N 2-[3-[[1-(4-chlorobenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C=CC(Cl)=CC=3)C=2C)=C1 YGIKSALMJUFCTG-UHFFFAOYSA-N 0.000 description 1
- CZMXEBXOLTWIEN-UHFFFAOYSA-N 2-[3-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]acetic acid Chemical compound CC1=C(CC=2C=C(OCC(O)=O)C=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CZMXEBXOLTWIEN-UHFFFAOYSA-N 0.000 description 1
- UZJIHIMYKLEBBQ-UHFFFAOYSA-N 2-[3-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]propanoic acid Chemical compound CC1=C(CC=2C=C(OC(C)C(O)=O)C=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 UZJIHIMYKLEBBQ-UHFFFAOYSA-N 0.000 description 1
- WTIUDROYDYCRCV-UHFFFAOYSA-N 2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(OC(C)(C)C(O)=O)C=CC=2)=C1C WTIUDROYDYCRCV-UHFFFAOYSA-N 0.000 description 1
- VHWYQIHRMGSPNU-UHFFFAOYSA-N 2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(OCC(O)=O)C=CC=2)=C1C VHWYQIHRMGSPNU-UHFFFAOYSA-N 0.000 description 1
- OFCWBJAYEIROGZ-UHFFFAOYSA-N 2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(OC(C)C(O)=O)C=CC=2)=C1C OFCWBJAYEIROGZ-UHFFFAOYSA-N 0.000 description 1
- APRSDJAYLLJNFZ-UHFFFAOYSA-N 2-[3-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C=C4C=CC=CC4=CC=3)C=2C)=C1 APRSDJAYLLJNFZ-UHFFFAOYSA-N 0.000 description 1
- YAGQPGVXBAGTLQ-UHFFFAOYSA-N 2-[4-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]acetic acid Chemical compound CC1=C(CC=2C=CC(OCC(O)=O)=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 YAGQPGVXBAGTLQ-UHFFFAOYSA-N 0.000 description 1
- PEADEDULWAZELC-UHFFFAOYSA-N 2-methyl-2-[2-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C12=CC(OC(F)(F)F)=CC=C2N(C(=O)C=2C=C3C=CC=CC3=CC=2)C(C)=C1CC1=CC=CC=C1OC(C)(C)C(O)=O PEADEDULWAZELC-UHFFFAOYSA-N 0.000 description 1
- PZKINEIEKOPLJY-UHFFFAOYSA-N 2-methyl-2-[3-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C12=CC(OC(F)(F)F)=CC=C2N(C(=O)C=2C=C3C=CC=CC3=CC=2)C(C)=C1CC1=CC=CC(OC(C)(C)C(O)=O)=C1 PZKINEIEKOPLJY-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VPDHYUHZLMBWFJ-UHFFFAOYSA-N Cc1c(Cc(cccc2)c2OCC(O)O)c2cc(OC(F)(F)F)ccc2[n]1C(c(cc1)ccc1OC)=O Chemical compound Cc1c(Cc(cccc2)c2OCC(O)O)c2cc(OC(F)(F)F)ccc2[n]1C(c(cc1)ccc1OC)=O VPDHYUHZLMBWFJ-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22077800P | 2000-07-25 | 2000-07-25 | |
| PCT/US2001/022979 WO2002008188A1 (en) | 2000-07-25 | 2001-07-20 | N-substituted indoles useful in the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513076A JP2004513076A (ja) | 2004-04-30 |
| JP2004513076A5 true JP2004513076A5 (enExample) | 2008-05-22 |
Family
ID=22824932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514095A Withdrawn JP2004513076A (ja) | 2000-07-25 | 2001-07-20 | 糖尿病治療で有用なｎ−置換インドール類 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6525083B2 (enExample) |
| EP (1) | EP1305285B1 (enExample) |
| JP (1) | JP2004513076A (enExample) |
| AT (1) | ATE362468T1 (enExample) |
| AU (2) | AU7705601A (enExample) |
| CA (1) | CA2415742A1 (enExample) |
| DE (1) | DE60128475T2 (enExample) |
| WO (1) | WO2002008188A1 (enExample) |
Families Citing this family (178)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| PE20020323A1 (es) * | 2000-08-22 | 2002-06-13 | Novartis Ag | COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| HUP0401081A3 (en) * | 2000-12-21 | 2010-06-28 | Sanofi Aventis Deutschland | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use |
| RS20100015A (sr) | 2001-01-26 | 2010-12-31 | Schering Corporation | Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| PT1355644E (pt) | 2001-01-26 | 2006-11-30 | Schering Corp | Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia |
| US7025985B2 (en) * | 2001-05-28 | 2006-04-11 | Kanebo, Ltd. | Dihydroxyphenyl compounds and glucoside compounds thereof |
| KR100838422B1 (ko) * | 2001-05-28 | 2008-06-16 | 가오가부시끼가이샤 | 지방분해 촉진제 및 이를 함유하는 체중감량용 피부화장료, 음식품 조성물 및 그 작용에 기초하는 체중 감량 방법 |
| US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| US6869975B2 (en) | 2001-09-14 | 2005-03-22 | Tularik Inc. | Linked biaryl compounds |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| EP1429756B1 (en) | 2001-09-21 | 2006-11-22 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
| PE20040291A1 (es) * | 2002-03-22 | 2004-07-02 | Novartis Ag | COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| WO2003088962A1 (en) * | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
| ITMI20021012A1 (it) * | 2002-05-13 | 2003-11-13 | Giovanni Scaramuzzino | Combinazione di un inibitore dell'enzima hmg-coa reduttasi e di un estere nitrato |
| EP1388352A1 (en) * | 2002-08-08 | 2004-02-11 | Laboratoires Fournier S.A. | Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment |
| JP4340232B2 (ja) | 2002-08-29 | 2009-10-07 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病活性を有するインドール類 |
| NZ538031A (en) * | 2002-08-29 | 2007-10-26 | Merck & Co Inc | Indoles having anti-diabetic activity |
| NZ537979A (en) * | 2002-09-12 | 2007-08-31 | Hoffmann La Roche | N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes |
| JP2006508188A (ja) | 2002-11-06 | 2006-03-09 | シェーリング コーポレイション | 脱髄の処置のためのコレステロール吸収インヒビター |
| DE10300099A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indol-Phenylsulfonamid-Derivate |
| CN102558155A (zh) | 2003-01-14 | 2012-07-11 | 阿伦纳药品公司 | 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗 |
| US7572922B2 (en) | 2003-01-27 | 2009-08-11 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| DE602004016123D1 (de) | 2003-03-07 | 2008-10-09 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| WO2004092146A2 (en) * | 2003-04-14 | 2004-10-28 | The Institutes For Pharmaceutical Discovery, Llc | N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes |
| WO2004098510A2 (en) * | 2003-04-30 | 2004-11-18 | Beth Israel Deaconess Medical Center | Cystic fibrosis therapy |
| US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| WO2004099168A2 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Substituted carboxylic acids |
| WO2004100895A2 (en) * | 2003-05-13 | 2004-11-25 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders |
| US20060160834A1 (en) * | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
| WO2004108126A1 (en) * | 2003-06-06 | 2004-12-16 | Snowden Pharmaceuticals, Llc | Fibric acid derivatives for the treatment of irritable bowel syndrome |
| TWI335328B (en) | 2003-07-14 | 2011-01-01 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto |
| DE10335449A1 (de) * | 2003-08-02 | 2005-02-17 | Bayer Healthcare Ag | Bicyclische Indolinsulfonamid-Derivate |
| DE10337839A1 (de) * | 2003-08-18 | 2005-03-17 | Bayer Healthcare Ag | Indolin-Derivate |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
| WO2005049573A1 (en) | 2003-11-05 | 2005-06-02 | F. Hoffmann-La Roche Ag | Phenyl derivatives as ppar agonists |
| RU2367659C2 (ru) | 2003-11-05 | 2009-09-20 | Ф.Хоффманн-Ля Рош Аг | Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar) |
| WO2005049572A1 (en) * | 2003-11-05 | 2005-06-02 | F. Hoffmann-La Roche Ag | Benzannelated compounds as ppar activators |
| EP1689389A4 (en) | 2003-12-04 | 2009-06-17 | Nat Health Research Institutes | Indole compounds |
| TWI297606B (en) * | 2004-01-16 | 2008-06-11 | Nat Health Research Institutes | Cancer therapy |
| JP2007534702A (ja) * | 2004-04-26 | 2007-11-29 | バンダービルト・ユニバーシティ | 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体 |
| US20080076810A1 (en) * | 2004-05-28 | 2008-03-27 | Weiguo Lui | Benzoureas Having Anti-Diabetic Activity |
| JP2008500991A (ja) * | 2004-05-29 | 2008-01-17 | ７ティーエム ファーマ エイ／エス | 医学的使用のためのｃｒｔｈ２レセプターリガンド |
| CN1964947A (zh) | 2004-06-04 | 2007-05-16 | 默克公司 | 吡唑衍生物、包含其的组合物及其用法 |
| CN1980659A (zh) | 2004-07-02 | 2007-06-13 | 默克公司 | 具有抗糖尿病活性的吲哚类 |
| CA2574147A1 (en) | 2004-07-22 | 2006-02-09 | Linda Brockunier | Substituted pyrazoles, compositions containing such compounds and methods of use |
| JP2008508238A (ja) | 2004-07-30 | 2008-03-21 | ラボラトリオス・サルバト・ソシエダッド・アノニマ | Ｐｐａｒガンマモジュレータとしてのチロシン誘導体 |
| RU2448977C2 (ru) * | 2004-09-16 | 2012-04-27 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью |
| JP2008019169A (ja) * | 2004-10-25 | 2008-01-31 | Osaka Univ | 新規ｐｐａｒ調節剤およびそのスクリーニング方法 |
| AU2005307718A1 (en) * | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids for the treatment of diabetes |
| US7579319B2 (en) * | 2004-12-06 | 2009-08-25 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| FR2880887B1 (fr) * | 2005-01-14 | 2009-01-30 | Merck Sante Soc Par Actions Si | Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |
| WO2006096564A1 (en) | 2005-03-04 | 2006-09-14 | Merck & Co., Inc. | Fused aromatic compounds having anti-diabetic activity |
| EP1890715A4 (en) * | 2005-04-29 | 2009-10-28 | Univ California | PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| WO2006125651A2 (en) * | 2005-05-24 | 2006-11-30 | Dsm Ip Assets B.V. | Ligustilide derivatives for the treatment of inflammatory disorders |
| AU2006269503A1 (en) | 2005-07-06 | 2007-01-18 | Merck & Co., Inc. | Antidiabetic oxazolidinediones and thiazolidinediones |
| WO2007015999A2 (en) | 2005-07-26 | 2007-02-08 | Merck & Co., Inc. | Process for synthesizing a substituted pyrazole |
| US20070161006A1 (en) * | 2006-01-10 | 2007-07-12 | Vita Genomics, Inc. | Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma |
| ES2354390T3 (es) * | 2006-04-11 | 2011-03-14 | Arena Pharmaceuticals, Inc. | Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo. |
| PE20071221A1 (es) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| WO2007149456A2 (en) | 2006-06-19 | 2007-12-27 | Vanderbilt University | Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
| KR20090066289A (ko) | 2006-09-08 | 2009-06-23 | 로드아일랜드하스피틀 | 알코올 유발성 뇌 질환의 치료, 예방 및 역행 |
| JP5570223B2 (ja) | 2007-01-26 | 2014-08-13 | カネック ファーマ インコーポレイテッド | タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）阻害剤としての縮合芳香族ジフルオロメタンホスホネート |
| ES2400293T3 (es) * | 2007-02-26 | 2013-04-08 | Merck Canada Inc. | Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4 |
| EP2155187B1 (en) | 2007-05-07 | 2016-05-25 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| US20080319221A1 (en) * | 2007-06-22 | 2008-12-25 | Bernd Junker | Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids |
| US20080319218A1 (en) * | 2007-06-22 | 2008-12-25 | Andreas Haubrich | Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate |
| US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| EP2195331B1 (en) | 2007-08-28 | 2013-11-20 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| FR2921366B1 (fr) * | 2007-09-26 | 2009-12-04 | Servier Lab | Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE102007054497B3 (de) * | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| US8759539B2 (en) | 2008-11-17 | 2014-06-24 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
| TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| CA2749930A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused heterocyclic antidiabetic compounds |
| US20110312967A1 (en) | 2009-01-23 | 2011-12-22 | Schering Corporation | Bridged and fused antidiabetic compounds |
| US8575166B2 (en) | 2009-02-05 | 2013-11-05 | Merck Sharp & Dohme Corp. | Phthalazine-containing antidiabetic compounds |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| EP2464228B1 (en) | 2009-08-13 | 2017-12-06 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| BR112012004335A8 (pt) | 2009-09-02 | 2016-06-21 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, uso do composto. |
| JP2013517272A (ja) | 2010-01-15 | 2013-05-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物としてのオキサジアゾール・ベータ・カルボリン誘導体 |
| EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| US8785634B2 (en) | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
| WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| US8980929B2 (en) | 2010-05-21 | 2015-03-17 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| MX2013003184A (es) | 2010-09-22 | 2013-06-07 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo. |
| RU2013124814A (ru) | 2010-10-29 | 2014-12-10 | Мерк Шарп Энд Домэ Корп. | Гетероциклические производные диазенийдиолата |
| ES2618812T3 (es) | 2011-01-20 | 2017-06-22 | Merck Sharp & Dohme Corp. | Antagonistas del receptor mineralocorticoide |
| JO3350B1 (ar) | 2011-03-07 | 2019-03-13 | Merck Sharp & Dohme | مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات |
| EP2693882B1 (en) | 2011-04-08 | 2017-06-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| WO2012139495A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| US9272987B2 (en) | 2011-05-02 | 2016-03-01 | Merck Sharp & Dohme Corp. | Diazeniumdiolate cyclohexyl derivatives |
| CN103687855A (zh) | 2011-06-02 | 2014-03-26 | 英特维特国际股份有限公司 | 咪唑衍生物 |
| CA2838079A1 (en) | 2011-06-16 | 2012-12-20 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| WO2012178142A1 (en) * | 2011-06-23 | 2012-12-27 | Metabolic Solutions Development Company, Llc | Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases |
| EP2760855B1 (en) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes |
| EP2765859B1 (en) | 2011-10-13 | 2017-01-18 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| US9346803B2 (en) | 2011-10-17 | 2016-05-24 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| US9018200B2 (en) | 2011-10-24 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as GPR119 agonists |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| WO2013068328A1 (en) | 2011-11-07 | 2013-05-16 | Intervet International B.V. | Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors |
| WO2013068439A1 (en) | 2011-11-09 | 2013-05-16 | Intervet International B.V. | 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors |
| US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
| US9073930B2 (en) | 2012-02-17 | 2015-07-07 | Merck Sharp & Dohme | Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| US20150057220A1 (en) | 2012-04-16 | 2015-02-26 | Kaneq Pharma Inc. | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
| US9315508B2 (en) | 2012-07-23 | 2016-04-19 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-IV inhibitors |
| WO2014099578A1 (en) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
| EP2934518B1 (en) | 2012-12-19 | 2020-02-19 | Merck Sharp & Dohme Corp. | Spirocyclic cetp inhibitors |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| WO2015112465A1 (en) | 2014-01-24 | 2015-07-30 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives as mgat2 inhibitors |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2016018729A1 (en) | 2014-07-29 | 2016-02-04 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| CA2954475C (en) | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| EP3177287B1 (en) | 2014-08-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3177282B1 (en) | 2014-08-08 | 2021-10-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| CA3093383A1 (en) | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| EP3303342B1 (en) | 2015-05-27 | 2021-03-17 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| EP3322420B1 (en) | 2015-07-13 | 2021-12-29 | Merck Sharp & Dohme Corp. | Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein |
| EP3359191A4 (en) | 2015-10-05 | 2019-05-29 | Merck Sharp & Dohme Corp. | ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1 |
| US20190382363A1 (en) | 2015-11-30 | 2019-12-19 | Merck Sharp & Dohme Corp. | Aryl sulfonamides as blt1 antagonists |
| EP3383869B1 (en) | 2015-11-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Aryl sulfonamides as blt1 antagonists |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
| US10414775B2 (en) | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| WO2018034918A1 (en) | 2016-08-15 | 2018-02-22 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| US11008313B2 (en) | 2016-09-20 | 2021-05-18 | Merck Sharp & Dohme Corp. | Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders |
| CA3043206A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| KR20190078646A (ko) | 2016-11-18 | 2019-07-04 | 머크 샤프 앤드 돔 코포레이션 | 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체 |
| WO2018107415A1 (en) | 2016-12-15 | 2018-06-21 | Merck Sharp & Dohme Corp. | Hydroxy isoxazole compounds useful as gpr120 agonists |
| KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
| AU2019280822A1 (en) | 2018-06-06 | 2021-01-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| IL321719A (en) | 2018-06-21 | 2025-08-01 | Merck Sharp ַ& Dohme Llc | Pcsk9 antagonist compounds |
| EP3946324B1 (en) | 2019-04-04 | 2025-07-30 | Merck Sharp & Dohme LLC | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
| WO2020236690A1 (en) | 2019-05-22 | 2020-11-26 | Merck Sharp & Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| WO2020236688A1 (en) | 2019-05-22 | 2020-11-26 | Merck Sharp & Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| WO2021041770A1 (en) | 2019-08-30 | 2021-03-04 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
| EP3842060A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
| EP3842449A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
| EP3842061A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
| US11787810B2 (en) | 2020-05-18 | 2023-10-17 | Merck Sharp & Dohme Llc | Diacylglyceride O-acyltransferase 2 inhibitors |
| TW202229232A (zh) | 2020-10-08 | 2022-08-01 | 美商默沙東藥廠 | 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之吲哚酮衍生物的製備 |
| MX2024002146A (es) | 2021-08-19 | 2024-03-08 | Merck Sharp & Dohme Llc | Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9. |
| EP4540267B1 (en) | 2022-06-15 | 2026-04-15 | Merck Sharp & Dohme LLC | Cyclic peptides for trapping interleukin-1 beta |
| IL321166A (en) | 2022-12-02 | 2025-07-01 | Merck Sharp & Dohme Llc | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
| US20250152658A1 (en) | 2023-11-14 | 2025-05-15 | Merck Sharp & Dohme Llc | Cyclic peptide for trapping interleukin-1 beta |
| WO2025128805A1 (en) | 2023-12-15 | 2025-06-19 | Merck Sharp & Dohme Llc | A cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders |
| US20260022125A1 (en) | 2024-07-19 | 2026-01-22 | Merck Sharp & Dohme Llc | Pyrrolopyridazine vegfr inhibitors |
| WO2026096330A1 (en) | 2024-10-28 | 2026-05-07 | Merck Sharp & Dohme Llc | Glp-1 receptor agonists and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3564009A (en) | 1966-01-13 | 1971-02-16 | Sumitomo Chemical Co | Process for producing 1-acylindole derivatives |
| CH605742A5 (en) | 1973-11-29 | 1978-10-13 | Crc Ricerca Chim | 1-Benzoyl-2-methyl-indole derivs. |
| AU4649189A (en) | 1988-11-14 | 1990-06-12 | Upjohn Company, The | Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
| JPH0764841B2 (ja) | 1990-10-03 | 1995-07-12 | ファイザー製薬株式会社 | インドール誘導体およびその用途 |
| WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
| US5527819A (en) | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| PT633886E (pt) | 1992-04-03 | 2001-03-30 | Upjohn Co | Aminas biciclicas-heterociclicas farmaceuticamente activas |
| ZA939516B (en) * | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| US5686481A (en) * | 1993-12-21 | 1997-11-11 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| CA2194984C (en) | 1994-07-26 | 2002-07-02 | John Eugene Macor | 4-indole derivatives as serotonin agonists and antagonists |
| RU2152385C1 (ru) | 1994-07-27 | 2000-07-10 | Санкио Компани Лимитед | Гетероциклические соединения, применимые в качестве аллостерических эффекторов при мускариновых рецепторах |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| ATE246686T1 (de) * | 1995-03-09 | 2003-08-15 | Kyowa Hakko Kogyo Kk | Pyrrolocarbazolderivate |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| EP0922028A1 (en) | 1996-08-26 | 1999-06-16 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
| CA2322163A1 (en) | 1998-02-25 | 1999-09-02 | John Mckew | Inhibitors of phospholipase a2 |
| PL343007A1 (en) * | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
| SK12742000A3 (sk) | 1998-02-25 | 2001-05-10 | Genetics Institute, Inc. | Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie |
| EE200100323A (et) * | 1998-12-18 | 2002-08-15 | Axys Pharmaceuticals, Inc. | (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena |
-
2001
- 2001-07-20 JP JP2002514095A patent/JP2004513076A/ja not_active Withdrawn
- 2001-07-20 AU AU7705601A patent/AU7705601A/xx active Pending
- 2001-07-20 WO PCT/US2001/022979 patent/WO2002008188A1/en not_active Ceased
- 2001-07-20 CA CA002415742A patent/CA2415742A1/en not_active Abandoned
- 2001-07-20 DE DE60128475T patent/DE60128475T2/de not_active Expired - Fee Related
- 2001-07-20 EP EP01954836A patent/EP1305285B1/en not_active Expired - Lifetime
- 2001-07-20 AT AT01954836T patent/ATE362468T1/de not_active IP Right Cessation
- 2001-07-20 AU AU2001277056A patent/AU2001277056B2/en not_active Ceased
- 2001-07-25 US US09/912,961 patent/US6525083B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003523336A5 (enExample) | ||
| JP2006500384A5 (enExample) | ||
| US7495020B2 (en) | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | |
| US7393960B2 (en) | Indoles having anti-diabetic activity | |
| JP2007502264A5 (enExample) | ||
| AU2002251978A1 (en) | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | |
| AU2003256911B2 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| JP2005502600A5 (enExample) | ||
| JP2004513076A (ja) | 糖尿病治療で有用なｎ−置換インドール類 | |
| JP2010529203A5 (enExample) | ||
| JP2008536947A (ja) | アリールアルキル酸誘導体およびそれらの使用 | |
| JP2018504438A5 (enExample) | ||
| US7524882B2 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| US20150051144A1 (en) | Compounds for the treatment of dyslipidemia and other diseases | |
| JP2007531764A5 (enExample) | ||
| JP2007531763A5 (enExample) | ||
| US20070173434A1 (en) | Antidiabetic oxazolidinediones and thiazolidinediones | |
| US7629372B2 (en) | Compounds for the treatment of dyslipidemia and other lipid disorders | |
| KR100806004B1 (ko) | 선택적 페록시좀 증식제 활성화 수용체 조절제 | |
| JP2009500355A (ja) | 抗糖尿病性オキサゾリジンジオン及びチアゾリジンジオン | |
| JP2008501027A (ja) | 抗糖尿病活性をもつベンゾ尿素 | |
| CN1319956C (zh) | 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用 | |
| JP2008526904A (ja) | ヒドロキシフェノール誘導体、その調製方法、それらを含む医薬組成物、およびその治療的使用 | |
| CN101098844A (zh) | 苯基苯甲酸衍生物、其制备方法、含有它们的药物组合物以及治疗应用 |